JANX (Janux Therapeutics) FCF Margin %: -337.80% (As of Mar. 2026)


JANX Janux Therapeutics Inc JANX
46 GF Score
Price $14.81
GF Value $39.21
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Janux Therapeutics FCF Margin %?

Janux Therapeutics JANX +1.06% 46 FCF Margin % is -337.80% as of Mar. 2026. GuruFocus rates JANX with a GF Score™ of 46/100 and a GF Value™ of $39.21 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 960 Biotechnology companies, Janux Therapeutics ranks worse than 73.96% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Janux Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-12.61 Mil. Janux Therapeutics's Revenue for the three months ended in Mar. 2026 was $3.73 Mil. Therefore, Janux Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was -337.80%.

As of today, Janux Therapeutics's current FCF Yield % is -8.69%.

The historical rank and industry rank for Janux Therapeutics's FCF Margin % or its related term are showing as below:

JANX' s FCF Margin % Range Over the Past 10 Years
Min: -832.78   Med: -573.24   Max: -417.2
Current: -571.56

During the past 7 years, the highest FCF Margin % of Janux Therapeutics was -417.20%. The lowest was -832.78%. And the median was -573.24%.

JANX's FCF Margin % is ranked worse than
73.96% of 960 companies
in the Biotechnology industry
Industry Median: -85.21 vs JANX: -571.56

Janux Therapeutics FCF Margin % Related Terms

Janux Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Janux Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Janux Therapeutics FCF Margin % Chart

Janux Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial -507.51 -573.24 -648.58 -417.20 -832.78

Janux Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -129.49 0.00 -337.80

JANX vs ANNX, XNCR, SPRY: FCF Margin % Comparison

For the Biotechnology subindustry, Janux Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Janux Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Janux Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Janux Therapeutics's FCF Margin % falls into.


JANX
46GF Score
Janux Therapeutics Inc JANX
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Janux Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Janux Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-83.278/10
=-832.78 %

Janux Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-12.61/3.733
=-337.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -337.80% mean?
Janux Therapeutics (JANX) has a FCF Margin % of -337.80% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Janux Therapeutics and its competitors. According to the industry distribution chart, Janux Therapeutics ranks #710 out of 960 companies in the Biotechnology industry, placing it in the top 74%.
Is Janux Therapeutics' FCF Margin % too high?
Janux Therapeutics' current FCF Margin % is -337.80%. Based on the distribution chart, Janux Therapeutics ranks #710 out of 960 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Janux Therapeutics has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Janux Therapeutics' FCF Margin % compare to ANNX and XNCR?
According to the Biotechnology industry distribution chart, Janux Therapeutics ranks #710 out of 960 companies for FCF Margin %. This places Janux Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Janux Therapeutics and its competitors. Janux Therapeutics's current FCF Margin % is -337.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Janux Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Janux Therapeutics (JANX) is currently considered Possible Value Trap. The stock's GF Value™ is $39.21, compared to a current price of $14.81 — trading 62.2% below its estimated fair value. The current FCF Margin % is -337.80%. Janux Therapeutics' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Janux Therapeutics (JANX), the current FCF Margin % is -337.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Janux Therapeutics (JANX) Overvalued in 2026?

Based on GuruFocus' analysis, Janux Therapeutics stock appears to be undervalued. The current stock price of $14.81 is trading 62.2% below its estimated GF Value™ of $39.21. GuruFocus considers Janux Therapeutics to be Possible Value Trap.

Key valuation signals for JANX:

  • FCF Margin %: -337.80%
  • GF Value™: $39.21 vs. price of $14.81 (62.2% below fair value)
  • GF Score™: 46/100 with 5 warning signs

No single metric tells the full story. See the JANX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Janux Therapeutics Business Description

Address 10955 Vista Sorrento Parkway, Suite 200, San Diego, CA, USA, 92130
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
46GF Score

Get the complete analysis for JANX

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.81
Price
$39.21
GF Value